Drug Profile
WAY 152288
Alternative Names: WAY 152,288Latest Information Update: 15 Jan 2004
Price :
$50
*
At a glance
- Originator Wyeth
- Class Antibacterials; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 15 Jan 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 27 Mar 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are both now called Wyeth
- 27 Oct 1998 Preclinical development for Bacterial infections in USA (Unknown route)